Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of IMG-7289 (Bomedemstat) in essential thrombocythemia
2019-003659-13Phase 2Completed
- Sponsor
- Imago BioSciences, Inc.
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bomedemstat in thrombocythemia, sponsored by Imago BioSciences, Inc. Primary endpoint: Primary: Safety and tolerability of IMG-7289. Started Mar 2020; status: completed.
02
Drugs
bomedemstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on 2019-003659-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003659-13.